Mucoepidermoid carcinoma
diseaseOn this page
Also known as MECMUCCmucoepidermoid carcinoma (morphologic abnormality)mucoepidermoid tumormucoepidermoid tumorsmucoepidermoid tumourmucoepidermoid tumourstumor, mucoepidermoidtumors, mucoepidermoid
Summary
Mucoepidermoid carcinoma (MONDO:0003036) is a cancer (an umbrella term covering 12 Mondo subtypes) and 3 clinical trials. Top therapeutic interventions include rimiducid and trastuzumab botidotin. A subtype of mucinous adenocarcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Umbrella term: 12 Mondo subtypes
- Clinical trials: 3
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | mucoepidermoid carcinoma |
| Mondo ID | MONDO:0003036 |
| MeSH | D018277, D018298 |
| DOID | DOID:163, DOID:4531 |
| ICD-11 | 287052516 |
| NCIT | C3772 |
| UMLS | C0206694 |
| MedGen | 61662 |
| GARD | 0010671 |
| Is cancer (heuristic) | yes |
Also known as: MEC · MUCC · mucoepidermoid carcinoma · mucoepidermoid carcinoma (morphologic abnormality) · mucoepidermoid tumor · mucoepidermoid tumors · mucoepidermoid tumour · mucoepidermoid tumours · tumor, mucoepidermoid · tumors, mucoepidermoid
Disease family
This is a subtype of mucinous adenocarcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma › mucinous adenocarcinoma › mucoepidermoid carcinoma
Related subtypes (16): breast mucinous carcinoma, extrahepatic bile duct mucinous adenocarcinoma, cervical mucinous adenocarcinoma, fallopian tube mucinous adenocarcinoma, endometrial mucinous adenocarcinoma, rectum mucinous adenocarcinoma, gallbladder mucinous adenocarcinoma, colloid carcinoma of the pancreas, colon mucinous adenocarcinoma, ovarian mucinous adenocarcinoma, mucinous cystadenocarcinoma, acinar prostate mucinous adenocarcinoma, mucinous gastric adenocarcinoma, lung colloid adenocarcinoma, mucinous pancreas adenocarcinoma, salivary gland mucinous adenocarcinoma
Subtypes (12): trachea mucoepidermoid carcinoma, thymic mucoepidermoid carcinoma, mucoepidermoid breast carcinoma, extrahepatic bile duct mucoepidermoid carcinoma, cutaneous mucoepidermoid carcinoma, lacrimal gland mucoepidermoid carcinoma, mucoepidermoid esophageal carcinoma, laryngeal mucoepidermoid carcinoma, pulmonary mucoepidermoid carcinoma, thyroid gland mucoepidermoid carcinoma, paranasal sinus mucoepidermoid carcinoma, oral cavity mucoepidermoid carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 3.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE1/PHASE2 | 1 |
| PHASE1 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03602079 | PHASE1/PHASE2 | COMPLETED | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene |
| NCT04249947 | PHASE1 | TERMINATED | P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) |
| NCT01586767 | Not specified | UNKNOWN | Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| RIMIDUCID | 2 | 1 |
| TRASTUZUMAB BOTIDOTIN | 2 | 1 |
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.